Fig. 5: Decreased IDO1 in BMDCs induced by a high-fat diet can be modulated by SIRT1.
From: Sirtuin 1 regulates the phenotype and functions of dendritic cells through Ido1 pathway in obesity
qPCR of Ido1 from BMDCs/SD and BMDCs/HFD, under RES [50 μM], EX-527 [20 μM] treatment or no treatment (A). Liquid Chromatography coupled to Mass Spectrometry (LC–MS/MS) of kynurenine pathway intermediates molecules, Tryptophan (TRP), Kynurenine (KYN) and Quinolinic Acid (QA), from BMDCs/SD and BMDCs/HFD, under RES, EX-527 treatment or no treatment (B). LC–MS/MS Kynurenine pathway enzymes (Indoleamine dioxygenase 1(IDO1), Kynurenine 3-monooxygenase (KMO), Kynureninase (KYNU), 3-Hhydroxyanthranillic acid dioxygenase (3-HAAO), quinolinate phosporibosyltransferase (QPRT), Neuraminidase (NA), mononucleotide adenylyltransferase (NMNAT) and Nicotinamidase (NADS)) from BMDCs/SD and BMDCs/HFD, under RES, EX-527 treatment or no treatment (C). LC–MS/MS Kynurenine pathway metabolites (Tryptophan (TRP), Kynurenine (KYN), Quinolinic Acid (QA), 3-Hydroxykynurenine 3-HK), 3-hydroxyanthranillic acid (3-HANA), nicotinic acid mononucleotide (NaMN) and nicotinic acid mononucleotide (NaMN)) from BMDCs/SD and BMDCs/HFD, under RES, EX-527 treatment or no treatment (D). MFI of MHC-II, and CD40 from BMDCs/SD and BMDCs/HFD, under RES, EX-527 treatment or no treatment, extracted from WT and IDOKO (Ido Knockout) mice (E–H). ELISA of IL-12p40 and TGF-β (pg/ml) in the supernatant from BMDCs/SD and BMDCs/HFD, under RES, EX-527 treatment or no treatment, extracted from WT and IDOKO mice (I–L). qPCR analysis of Sirt1 in BMDCs from SD and HFD groups, including BMDCs from WT and IDO KO mice (M). The significance values (p) followed the order: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001, which were treated by the One-way ANOVA test or t-test when necessary, using GraphPad Prism®. The graphs illustrations are a representative experiment of three distinct experiments, which contained 3–5 animals per group.
